UNITED ~~STATES SECURITIES~~ STATESSECURITIES AND EXCHANGE ~~COMMISSION WASHINGTON~~COMMISSIONWASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~February~~March 2417, 2026

BIOATLA, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware	~~001-39787~~	~~85-1922320~~	001-39787	85-1922320
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
(State or Other Jurisdictionof Incorporation)			(Commission File Number)	(IRS EmployerIdentification No.)
11085 Torreyana Road
San Diego, California		~~92121~~		92121
(Address of Principal Executive Offices)		~~(Zip Code)~~		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: 858 558-0708

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		~~Trading Symbol~~TradingSymbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		BCAB		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 25.02 ~~Results~~Departure of ~~Operation~~Directors ~~and~~or ~~Financial~~Certain ~~Condition.~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory

~~The~~Arrangements ~~information set forth in Item 7.01~~ of ~~this~~ ~~Current~~Certain ~~Report on Form 8-K filed by BioAtla, Inc~~Officers. (the “Company” or “BioAtla”) on March 2, 2026, with respect to the Company’s preliminary estimate of its cash and cash equivalents as of December 31, 2025 is incorporated herein by reference. Such information is preliminary, has not been audited and is subject to change pending completion of the Company’s audited financial statements for the year ended December 31, 2025. It is possible that the Company or its independent registered public accounting firm may identify items that require the Company to make adjustments to the amounts included in this Item 2.02, and such changes could be material. Additional information and disclosures would also be required for a more complete understanding of the Company’s financial position and results of operations as of December 31, 2025.

~~The~~Mr. ~~information~~Vasquez ~~included in this Item 2.02~~ and ~~Item 7~~Dr.~~01,~~ isSievers ~~being~~Retention furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act, except as shall be expressly set forth by specific reference in such filing.Bonuses

~~Item~~In 2lieu of a bonus plan for the first eight months of 2026, on March 17, 2026, the Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of BioAtla, Inc.05 ~~Costs~~(the ~~Associated~~“Company”) ~~with~~approved ~~Exit~~a orretention ~~Disposal~~bonus ~~Activities~~program for certain Company employees, including the following executive officers: Christian Vasquez, the Company’s Chief Financial Officer, and Eric Sievers, M.D., the Company’s Chief Medical Officer. For 2025, no bonuses were earned by any of the Company’s employees, including the Company’s executive officers, as the Compensation Committee had earlier determined that threshold achievement of certain financial milestones and business objectives were not met for 2025. In addition, the Compensation Committee and the Board determined that there would be no salary increases for 2026 for any of the Company’s employees, including its executive officers.

OnThe ~~March~~retention 2bonuses for Mr. Vasquez and Dr. Sievers each provide for two separate cash payouts contingent upon the achievement of (i) certain financial and capital raising milestones by May 31, 2026 (“Milestone #1”) and (ii) certain financial and capital raising milestones by August 31, 2026 (“Milestone #2”). With respect to Mr. Vasquez, the ~~Company~~target ~~announced a~~retention ~~workforce~~bonus ~~reduction~~amount for Milestone #1 is $37,222, representing 10% of ~~approximately~~Mr. 70Vasquez’s annual base salary, and the target retention bonus amount for Milestone #2 is $148,888, representing 40% of Mr. ~~The~~Vasquez’s ~~foregoing~~annual ~~actions~~base ~~were~~salary. ~~committed~~With respect to onDr. ~~February~~Sievers, 24the target retention bonus amount for Milestone #1 is $53,063, ~~2026~~representing 10% of Dr. Sievers’ base salary, and the target retention bonus amount for Milestone #2 is $212,252, representing 40% of Dr. Sievers’ base salary. The payouts for Milestone #1 and Milestone #2 are ~~intended~~subject to ~~further cost-containment~~a ~~measures~~sliding scale. If a milestone achievement is exceeded by up to 20%, the payout is increased proportionally, up to a maximum of 120% of the target amount. If a milestone achievement is missed by up to 20%, the payout is reduced proportionally, to a minimum of 80% of the target amount. If a milestone achievement is missed by more than 20%, no payout is earned for that milestone. Any earned bonus in connection with ~~the~~Milestone ~~Company’s~~#1 ~~formal~~would ~~process~~be topayable ~~explore~~by June 30, 2026, and ~~evaluate~~any ~~strategic~~earned ~~options~~bonus toin ~~maximize shareholder~~connection ~~value~~with Milestone #2 would be payable by September 30, 2026.

~~The~~Each ~~total~~executive ~~cash~~officer ~~payments~~must ~~related to this workforce reduction are estimated to~~ be ~~between~~employed ~~$0.5~~by ~~and~~the ~~$0.6~~Company ~~million related to employee severance~~ and ~~benefit~~in ~~costs.~~good ~~The~~standing ~~Company expects~~at tothe ~~pay~~time ~~for~~of the ~~majority~~applicable ofpayout ~~these~~date ~~costs~~ in ~~the~~order ~~first~~to ~~quarter~~receive ofthe ~~2026~~applicable retention bonus.

~~The~~Dr. ~~estimates~~Short ofRetention the charges and expenditures that the Company expects to incur in connection with the above, and the timing thereof, are subject to a number of assumptions, and actual amounts may differ materially from estimates.Bonus

~~Item~~In ~~5.02~~lieu ~~Departure~~ of ~~Directors~~a orbonus ~~Certain~~plan ~~Officers;~~for ~~Election~~the offirst ~~Directors;~~eight ~~Appointment~~months of ~~Certain~~2026, ~~Officers;~~on ~~Compensatory~~March ~~Arrangements~~20, of2026, ~~Certain~~the ~~Officers~~Board approved a retention bonus program for Jay M. Short, Ph.D., the Company’s Chief Executive Officer. As described above, Dr. Short did not earn a bonus for 2025, or receive a salary increase for 2026.

~~Richard~~The ~~Waldron~~retention bonus for Dr. Short provides for a single cash payout contingent upon the achievement of certain financial and capital raising milestones by August 31, 2026. The target retention bonus amount is $449,712, representing 60% of Dr. Short’s ~~employment~~annual ~~and~~base ~~role as~~salary. ~~Chief~~The ~~Financial~~payout ~~Officer~~is subject to a sliding scale based on the level of milestone achievement. If the ~~Company~~milestone ~~will~~achievement ~~terminate~~is ~~effective~~exceeded asby up to 20%, the payout is increased proportionally, up to a maximum of ~~March~~120% 2of the target amount. If the milestone achievement is missed by up to 20%, the payout is reduced proportionally, to a minimum of 80% of the target amount. If the milestone achievement is missed by more than 20%, no payout is earned. Any earned bonus would be payable by September 30, 2026.

~~The Company has offered Mr~~Dr. ~~Waldon~~Short ~~severance pursuant~~must tobe aemployed ~~mutual~~by ~~separation~~the ~~agreement~~Company ~~providing for (i) a prorated portion of his salary~~ and ~~benefits~~in ~~through~~good ~~March~~standing ~~31,~~at ~~2026, (ii)~~the ~~extension~~time of the ~~exercise~~payout ~~period of his vested stock options from ninety (90) days to two (2) years from Mr. Waldron’s~~ date ~~of separation and (iii) accelerated vesting of 37,875 shares underlying Mr. Waldon’s restricted stock units,~~ in ~~exchange for~~order ato ~~general~~receive ~~release~~the ofretention ~~claims by Mr~~bonus. ~~Waldron.~~

~~Effective~~Item ~~March~~5.07. 2,Submission ~~2026,~~of ~~Chris~~Matters ~~Vasquez, the~~to ~~Company’s~~a ~~Chief~~Vote ~~Accounting~~of ~~Officer,~~Security ~~was appointed the Company’s Chief Financial Officer and principal financial officer~~Holders.

~~Mr.~~As ~~Vasquez,~~previously 50disclosed, ~~has~~on ~~served~~March ~~as the Chief Accounting Officer~~2, ~~Controller and Corporate Secretary of the Company since 2024~~2026, ~~as Corporate Controller of~~ the Company ~~from~~originally ~~2015 to~~convened ~~2024,~~a asspecial ~~Vice~~meeting ~~President~~ of ~~Finance~~stockholders ~~and Secretary of~~ (the ~~Company~~“Special ~~from~~Meeting”) ~~2020~~for tothe ~~2024~~sole ~~and~~purpose ~~as Senior Vice President~~ of ~~Finance~~adjourning of the ~~Company~~Special ~~from~~Meeting ~~2023~~ to ~~2024.~~a ~~Mr.~~later ~~Vasquez~~date ~~has over 20 years of finance~~ and ~~business experience working with both public and private companies~~time. ~~Prior~~At ~~to joining~~ the ~~Company,~~reconvened heSpecial ~~spent~~Meeting ~~seven~~on ~~years~~March at23, ~~Cricket Communications~~2026, ~~from~~there ~~October~~were ~~2008~~present, toin ~~October~~person ~~2015,~~virtually ~~through its~~or ~~acquisition~~ by ~~AT&T~~proxy, ~~where~~holders ~~his~~of ~~leadership~~50,698,581 ~~role~~shares ~~expanded to Associate Director~~ of ~~Accounting.~~common Hestock, ~~began~~or ~~his~~approximately ~~career~~68% ~~with~~of ~~KPMG in~~the ~~their~~total ~~San~~outstanding ~~Diego~~shares ~~office’s~~eligible ~~audit~~to ~~practice.~~be Mrvoted. ~~Vasquez~~The ~~received~~final ~~his~~voting BSresults ~~degree~~with inrespect ~~Accountancy~~to ~~from~~the ~~San~~proposal ~~Diego~~presented ~~State~~at ~~University and~~the isreconvened aSpecial ~~Certified~~Meeting ~~Public~~are ~~Accountant~~set inforth ~~the~~below: ~~state of California.~~

~~There are~~Proposal no1: ~~family~~The ~~relationships~~Merger between any director or executive officer of the Company and Mr. Vasquez, and there are no arrangements or understandings between Mr. Vasquez and any other person pursuant to which he was appointed to serve as the Company’s Chief Financial Officer. Mr. Vasquez is not a party to any arrangement or understanding with any person pursuant to which he was appointed as an officer of the Company, nor is he a party to any transactions required to be disclosed under Item 404(a) of Regulation S-K involving the Company or any of its subsidiaries.Proposal

~~Mr. Vasquez~~The ~~has~~Company’s ~~entered~~stockholders ~~into~~approved and adopted the ~~standard~~Agreement ~~indemnification~~and ~~agreement~~Plan ~~with~~of ~~the~~Merger, ~~Company~~as amended from time to time, aincluding ~~form~~pursuant to Amendment No. 1 to Agreement and Plan of Merger, which was ~~filed~~adopted asby ~~Exhibit~~the ~~10.15~~Board to of Directors of the Company’s ~~Annual~~and ~~Report~~executed onby ~~Form~~the ~~10-K~~parties ~~filed~~to ~~with~~that certain Agreement and Plan of Merger, dated as of January 30, 2026, by and between the ~~SEC~~Company onand ~~March~~its 28wholly owned subsidiary, ~~2025~~BA Merger Sub, ~~that~~Inc. (“Merger Sub”), pursuant to which Merger Sub will ~~remain~~merge inwith ~~effect.~~and into the Company (the “Merger” and such proposal, the “Merger Proposal”), by the following votes:

There will be no change in compensation for Mr. Vasquez in connection with his appointment as Chief Financial Officer.


Votes For	Votes Against	Abstentions	Broker Non-Votes
49,210,718	1,473,541	14,322	0

~~Item~~Because ~~7.01~~there ~~Regulation~~were FDsufficient votes to approve the Merger Proposal, the proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes in favor of the Merger Proposal, was not submitted for a vote at the reconvened Special Meeting.

AsAt ~~previously~~the ~~disclosed,~~effective ontime ~~February 8, 2026, The Nasdaq Stock Market LLC (“Nasdaq”) Office~~ of ~~General Counsel notified~~ the ~~Company that the Nasdaq Listing and Hearing Review Council (the “Listing Council”) has called for review Nasdaq’s February 6~~Merger, ~~2026, decision~~ (~~the “Delist Determination”~~i) toMerger ~~suspend~~Sub ~~trading~~will inmerge ~~the~~with ~~Company’s securities effective upon the open of the market on February 10, 2026,~~ and ~~ultimately~~into ~~delist~~ the Company~~’s securities from~~, ~~Nasdaq.~~with ~~Nasdaq had determined to suspend trading in~~ the Company’s ~~securities~~surviving ~~based upon (i)~~ the ~~Company’s non-compliance with~~Merger, ~~the $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2)~~ and (ii) ~~the~~ ~~Company’s~~every ~~failure~~fifty ~~to demonstrate compliance with the $2.5 million stockholders’ equity requirement under Nasdaq Listing Rule 5550~~(b50)~~(1),~~ ~~the~~shares ~~latter notwithstanding the Company’s prior compliance with the alternative threshold~~ of ~~$35 million~~common instock ~~market value~~ of ~~listed securities under Nasdaq Listing Rule 5550(b)(2) (~~the ~~“MVLS~~Company ~~Rule”)~~issued ~~for~~and 69outstanding, ~~consecutive~~or ~~trading~~held ~~days.~~as Intreasury ~~rendering its decision~~stock, ~~the~~will ~~Listing~~be ~~Council~~converted ~~also~~into ~~determined~~one ~~to stay~~(1) ~~any~~share ~~such suspension and delisting action pending the outcome~~ of ~~the Listing Council’s review. Accordingly, the Company’s~~ common stock ~~will~~of ~~continue to trade on Nasdaq during~~ the ~~Listing~~surviving ~~Council~~corporation, ~~review~~which ~~process.~~shall Itbe is the Company’s ~~understanding that~~ (the ~~Listing~~“Share ~~Council review process may take several weeks to a few months to complete~~Consolidation”). The Company ~~believes~~plans ~~that~~to ~~Nasdaq’s delay~~effect in the ~~consideration~~Merger and ~~confirmation of~~ the ~~Company’s~~Share ~~compliance~~Consolidation ~~status, its subsequent failure to issue a determination that the Company had evidenced compliance with the MVLS Rule~~ as ~~well~~soon as ~~Nasdaq’s~~possible ~~recent~~subject ~~decision~~ to ~~covertly~~required ~~overturn longstanding~~ Nasdaq ~~policy~~notice ~~regarding~~periods. ~~the~~The ~~use~~effective date of ~~super-voting~~the ~~stock~~Merger tohas ~~obtain~~not ~~shareholder~~been ~~approval~~determined ~~for~~and awill ~~reverse~~be ~~stock~~announced ~~split,~~by ~~has~~the ~~caused~~Company ~~and will~~at ~~cause~~least ~~irreparable~~two ~~harm~~business days prior to ~~the~~its ~~Company~~implementation.

As previously disclosed, on December 30, 2025, BioAtla entered into an Investment Agreement (the “Investment Agreement”) with Inversagen AI, LLC, a Delaware limited liability company (“Inversagen AI”), and Alliance International Resources Corp., a Nevada corporation (“AIRC”). Subject to completion of financings by Inversagen AI as set forth in the Investment Agreement, with the initial investment into Inversagen AI being led by AIRC, BioAtla agreed to sell common units of a wholly owned subsidiary, BA 3021 SPV LLC, a Delaware limited liability company (the “SPV”) to Inversagen AI in a private placement for $40 million over multiple closings (the “SPV Transaction”).SIGNATURES

InPursuant ~~connection~~to ~~with~~ the ~~ongoing~~requirements ~~review~~of by the ~~Listing~~Securities ~~Council~~Exchange ~~and~~Act ~~the~~of ~~recently announced formal process to explore and evaluate strategic options and related workforce reduction~~1934, ~~AIRC~~ ~~has not completed its investment into Inversagen AI, and~~ the ~~Company~~registrant ~~and~~has ~~Inversagen~~duly AIcaused ~~are~~this ~~currently~~report ~~in discussions with respect~~ to ~~potentially~~be ~~revising~~signed ~~the~~on ~~structure~~its ~~and~~behalf ~~timeline~~by ofthe ~~completing~~undersigned ~~the~~hereunto ~~SPV~~duly ~~Transaction~~authorized.

The Company can provide no assurance that the Listing Council’s review will result in the continued listing of the Company’s common stock on Nasdaq after the outcome of such review or that it will timely complete the SPV Transaction.


			BioAtla, Inc.

Date:	March 23, 2026	By:	/s/ Christian Vasquez
			Christian Vasquez Chief Financial Officer

As previously disclosed, on November 20, 2025, the Company entered into Pre-Paid Advance Agreements (the “PPAs”) with each of YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Yorkville”), Anson Investments Master Fund LP and Anson East Master Fund LP (collectively, the “Investors”). Pursuant to the PPAs, the Investors agreed to advance to the Company $7.5 million. Also on November 20, 2025 (the “Effective Date”), the Company entered into the Standby Equity Purchase Agreement (the “SEPA”) with Yorkville pursuant to which the Company has the right to sell to Yorkville up to $15.0 million of shares of Common Stock, subject to certain limitations and conditions set forth in the SEPA, during the 36 months following the Effective Date (such shares, the “SEPA Shares”).

As of December 31, 2025, the Company’s cash and cash equivalents were approximately $7.1 million. As of March 2, 2026, no amounts remained outstanding under the PPAs. At the Company’s option, the Company may sell SEPA Shares subject to satisfaction of the terms and conditions set forth in the SEPA, including but not limited to certain volume limitations.

The information included in this Item 7.01 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act, except as shall be expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

Formal Process to Explore and Evaluate Strategic Options

On March 2, 2026, the Company announced that it has initiated a formal process to explore and evaluate strategic options to maximize shareholder value, including sale of preclinical and clinical assets, licensing transactions, strategic partnerships or other corporate transactions. In connection with the evaluation of strategic alternatives, the Company is implementing a restructuring plan that includes a workforce reduction of approximately 70% percent as further described above in Item 2.05. A copy of the press release announcing the formal process is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Amendment No. 1 to Agreement and Plan of Merger

As previously disclosed, on January 30, 2026, the Company entered into the Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which (i) a wholly owned subsidiary (the “Merger Sub”) will merge with and into the Company, with the Company surviving (the “Merger”), (ii) every fifty (50) shares of Common Stock issued and outstanding, or held as treasury stock, will be converted into one (1) share of common stock of the surviving corporation, which shall be the Company, and (iii) the Company’s Amended and Restated Certificate of Incorporation would be amended and restated to, among other things, exempt future amendments to Article IV thereof from the supermajority voting requirements of Article IX and instead default to the voting requirements provided by Delaware law.

On March 2, 2026, the Company and Merger Sub entered into Amendment No. 1 to the Merger Agreement (“Amendment No. 1”) to provide that the Company’s Amended and Restated Certificate of Incorporation shall be unaffected by the Merger contemplated thereby and shall be the certificate of incorporation of the surviving corporation.

The foregoing description of Amendment No. 1 does not purport to be complete and is qualified in its entirety by reference to the text of Amendment No. 1, a copy of which is filed as Exhibit 1.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated herein by reference.

Forward-Looking Statements

This Current Report contains forward-looking statements. All statements other than statements of historical facts contained herein, including, but not limited to, statements concerning the intended benefits of the formal process; the timing and ability of the Company to complete the SPV Transaction; and statements regarding the percentage of workforce affected by, the estimated cash payment related to, and the timing of costs incurred from the reduction in force; preliminary estimate of cash and cash equivalents as of December 31, 2025; and the ability of the Company to sell SEPA Shares are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause the Company’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ include, among others: the ability to achieve the expected benefits of the Company’s workforce reduction, factors that raise substantial doubt about the Company’s ability to continue as a going concern and that the Company will need additional funding to continue development of its CAB technology platform and its CAB product candidates; the risk that preliminary or interim clinical results may not be indicative of results from later cohorts or larger populations; potential delays in clinical and preclinical trials; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, or regulatory approval dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; whether regulatory authorities will be satisfied with the design of and results from the clinical studies or take favorable regulatory actions based on results from the clinical studies; the Company’s dependence on the success of the Company’s CAB technology platform; the Company’s ability to enroll patients in the Company’s ongoing and future clinical trials; the successful selection and prioritization of assets to focus development on selected product candidates and indications; the Company’s ability to form collaborations and partnerships with third parties and the success of such collaborations and partnerships; the Company’s reliance on third parties for the manufacture and supply of the Company’s product candidates for clinical trials; the Company’s reliance on third parties to conduct the Company’s clinical trials and some aspects of the Company’s research and preclinical testing; potential adverse impacts due to geopolitical or macroeconomic events outside of the Company’s control, including health epidemics or pandemics; and those other risks and uncertainties described in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 27, 2025, the Company’s Quarterly Reports on Form 10-Q filed with the SEC on May 6, 2025, August 7, 2025 and November 13, 2025 and the Company’s subsequent filings with the SEC. Any forward-looking statements contained in this Current Report speak only as of the date hereof, and the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
1.1		Amendment No. 1 to Agreement and Plan of Merger, dated as of March 2, 2026, by and between BioAtla, Inc. and BA Merger Sub, Inc.
99.1		Press Release dated March 2, 2026.
104		Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			BioAtla, Inc.
Date:	March 2, 2026	By:	/s/ Jay M. Short, Ph.D.
			Jay M. Short, Ph.D. Chief Executive Officer

Filing Compare · BioAtla, Inc.